TAS3681

TAS-3681 · Taiho Oncology, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TAS3681, covering 2024-09-03 to 2024-09-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer [Phase 1]